OMNIVERSE: A Phase 1b/2 Study of Oral Azacitidine Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed (ND) Acute Myeloid Leukemia (AML)

Farhad Ravandi,Hetty E Carraway,Lilia Taningco,Kimberley Dilley,Eric Laille,Jing Gong,Daniel Lopes De Menezes,Andrew H Wei

doi:10.1182/blood-2021-147293

OMNIVERSE: A Phase 1b/2 Study of Oral Azacitidine Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed (ND) Acute Myeloid Leukemia (AML)

Farhad Ravandi, Hetty E Carraway + Show 6 more

https://doi.org/10.1182/blood-2021-147293

Copy DOI

Export

Save

Cite

Journal: Blood	Publication Date: Nov 5, 2021
Citations: 1

Affiliation: The University of Texas MD Anderson Cancer Center, Cleveland Clinic, Bristol-Myers Squibb (United States), Monash University, The Alfred Hospital

#Newly Diagnosed Acute Myeloid Leukemia #Equity Holder In Publicly-traded Company #Newly Diagnosed #Current Equity Holder #Acute Myeloid Leukemia #Publicly-traded Company #Advisory Committees #Research Funding #Venetoclax #Current Employment

Abstract
Full-Text
Similar Papers

Abstract

Listen

OMNIVERSE: A Phase 1b/2 Study of Oral Azacitidine Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed (ND) Acute Myeloid Leukemia (AML)

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

OMNIVERSE: A Phase 1b/2 Study of Oral Azacitidine Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed (ND) Acute Myeloid Leukemia (AML)